Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2012

Have drug combinations supplanted stem cell transplantation in myeloma?

View Full Paper
Ask AI
Bookmark
Share

Authors

APAntonio PalumboSemmelweis UniversityFCFederica CavalloAzienda Ospedaliera Citta' della Salute e della Scienza di Torino

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Palumbo et al. (2012) studied this question.

synapsesocial.com/papers/6a174c0195fbca339c8d8368https://doi.org/10.1182/asheducation-2012.1.335
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial2010 · 438 citations
  2. 2Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial2010 · 533 citations
  3. 3Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial2010 · 427 citations
  4. 4Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma2010 · 868 citations